BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/16/2022 11:52:43 AM | Browse: 173 | Download: 314
 |
Received |
|
2022-05-04 13:05 |
|
Peer-Review Started |
|
2022-05-04 13:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-06-11 04:41 |
|
Revised |
|
2022-06-22 05:12 |
|
Second Decision |
|
2022-08-15 06:43 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2022-08-16 21:20 |
|
Articles in Press |
|
2022-08-16 21:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-08-06 20:15 |
|
Typeset the Manuscript |
|
2022-08-30 19:40 |
|
Publish the Manuscript Online |
|
2022-09-16 11:52 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Wattana Leowattana, Tawithep Leowattana and Pathomthep Leowattana |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Wattana Leowattana, MD, MSc, PhD, Associate Professor, Professor, Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajavithi road, Rachatawee, Bangkok 10400, Thailand. wattana.leo@mahidol.ac.th |
| Key Words |
Atrial fibrillation; Human-induced pluripotent stem cell-derived atrial cardiomyocytes; Disease modeling; Maturation; Pharmacologic response; Personalized medicine |
| Core Tip |
New medications to treat atrial fibrillation (AF) without causing ventricular arrhythmias are urgently needed. However, access to atrial human tissue is restricted, a problem that may be largely addressed by the general availability of human induced pluripotent stem cell derived atrial cardiomyocytes (hiPSC-aCMs), which provide an excellent opportunity to investigate the pathophysiology of AF and the efficacy and toxicity of treatment options. The primary drawback of using hiPSC-aCMs is their immature phenotype. Several laboratories are researching CM maturation techniques, including culture conditions, electrical stimulation, and biophysical and biochemical features. The current strategies being investigated for use in the maturation of patient-specific hiPSC-aCMs and their application towards a tailored strategy for the pharmacologic management of AF are covered in this review. |
| Publish Date |
2022-09-16 11:52 |
| Citation |
Leowattana W, Leowattana T, Leowattana P. Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation. World J Clin Cases 2022; 10(27): 9588-9601 |
| URL |
https://www.wjgnet.com/2307-8960/full/v10/i27/9588.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v10.i27.9588 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
